EL
CCCC icon

EWA LLC’s C4 Therapeutics CCCC Stock Holding History

EWA LLC’s Portfolio CCCC Stock Details CCCC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$66K Sell
14,129
-443
-3% -$1.51K 0.01% 320
2026
Q1 		$38.3K Sell
14,572
-2,317
-14% -$5.46K 0.01% 276
2025
Q4 		$32.3K Sell
16,889
-2,621
-13% -$6.21K 0.01% 256
2025
Q3 		$43.3K Buy
19,510
+2,867
+17% +$6.88K 0.01% 219
2025
Q2 		$23.8K Buy
+16,643
New +$24.2K 0.01% 211

Other funds holding CCCC

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

EWA LLC's CCCC Position: Q2 2026 in Review

EWA LLC reduced its C4 Therapeutics (CCCC) stake by 3% in Q2 2026, selling an estimated $1.51K and leaving 14,129 shares worth $66K. The position accounts for 0.01% of the portfolio, ranked #320.

EWA LLC first reported a position in CCCC in Q2 2025 and has held it in 5 quarters since. 148 funds tracked by Wall St. Rank hold CCCC as of Q2 2026.

  • EWA LLC held 14,129 shares of C4 Therapeutics worth $66K as of Q2 2026.
  • EWA LLC sold 443 C4 Therapeutics shares in Q2 2026, an estimated $1.51K.
  • C4 Therapeutics made up 0.01% of EWA LLC's portfolio in Q2 2026, its #320 holding.
  • EWA LLC first reported a position in C4 Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • 148 funds tracked by Wall St. Rank held C4 Therapeutics as of Q2 2026.

Based on EWA LLC's 13F filing for Q2 2026, filed 14 Jul 2026.